ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
 PMID: 15917527       2005       Antimicrobial agents and chemotherapy
Abstract: In sequential passage experiments using HIV-1 LAI, two mutations (R41T and K70E) were selected.


  In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
 PMID: 16127074       2005       Antimicrobial agents and chemotherapy
Abstract: Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the d- and l-enantiomers of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for l-d4FC and I63L, K65R, K70N, K70E, or R172K for d-d4FC.


  Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
 PMID: 11511821       2001       Journal of acquired immune deficiency syndromes (1999)
Abstract: RT mutations previously selected by adefovir in vitro (K70E or K65R) did not develop in any patient.


  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
 PMID: 9660994       1998       Antimicrobial agents and chemotherapy
Abstract: In vitro experiments demonstrated that either a K65R or a K70E mutation in HIV reverse transcriptase (RT) was selected in the presence of adefovir, conferring a 16- or 9-fold decrease in susceptibility to adefovir, respectively.
Abstract: Viruses from two of the eight patients developed the K70E mutation while the patients were on therapy, but none of the viruses from patients developed the K65R RT substitution.


  National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
 PMID: 9687570       1998       Molecular pharmacology
Abstract: Genotypic analyses of samples from patients enrolled in a phase I/II clinical trial of adefovir dipivoxil demonstrated that the K70E RT mutation developed in two of 29 patients during extended therapy.
Abstract: Previous in vitro experiments have shown that HIV-1 recombinant viruses expressing either a K65R or a K70E mutation in reverse transcriptase (RT) have reduced sensitivity to PMEA and that the K70E mutant also has impaired replication capacity in vitro.
Abstract: The K70E mutant was also slightly impaired, whereas the K65R mutant was slightly more processive than wild-type.


  National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
 PMID: 8878611       1996       Antimicrobial agents and chemotherapy
Abstract: A recombinant virus carrying the K70E mutation was constructed and showed a 10-fold increase in its 50% inhibitory concentrations of PMEA and 2',3'-dideoxy-3'-thiacytidine but showed wild-type susceptibility levels to 2',3'-dideoxycytosine, 2',3'-dideoxyinosine,2',3'-didehydro-2'3'-dideoxythymidine, 3'-azido-3'-deoxythymidine, foscarnet, and two additional phosphonates, 9-[(R)-2-(phosphonomethoxy)propyl]adenine and 9-[2,5-dihydro-5-(phosphonomethoxy)-2-furanyl]adenine.
Abstract: Additionally, the K70E recombinant showed a minor reduction in growth kinetics compared with those of the wild-type virus in vitro.
Abstract: Sequence analyses of these PMEA-selected viruses demonstrated the presence of a novel lysine-to-glutamic acid mutation at amino acid 70 (K70E) in HIV reverse transcriptase.



Browser Board

 Co-occurred Entities




   Filtrator